CTLA4 and cancer: Antibodies targeting checkpoint molecules such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) or programmed cell death protein-1 (PD-1) have been approved and are in clinical practice for the therapy of a variety of cancers [5].